Benefits of IL Therapies in Patients with PP
Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.
EP: 1.Choosing the Right Psoriasis Treatment: Tailoring Therapy to Patient Characteristics
EP: 2.Screening for PsA and Selecting Right Biologic Therapy
EP: 3.Biologics for Psoriasis: TNF Blockers
EP: 4.Benefits of IL Therapies in Patients with PP
EP: 5.Understanding Comorbidities: Impact on Biologic Treatment Selection
EP: 6.Unraveling Boxed Warnings: Exploring/Examining Risks in Biologic Treatment Classes
EP: 7.Infectious Diseases and Biologic Treatment Selection
EP: 8.Understanding Biologics for Patients With IBD
EP: 9.Exploring Innovation: Recent Approvals and Novel Approaches to Psoriasis Treatment
EP: 10.Warnings and Precautions for Newer Psoriasis Treatments
EP: 11.When to Switch a Drug Class in Psoriasis Treatment
In this discussion among dermatologists, the focus is on the efficacy and safety of various biologics for treating plaque psoriasis, particularly TNF blockers, IL-23 blockers, and IL-17 blockers. The dermatologists express a preference for newer biologics due to their improved dosing schedules, efficacy, and safety profiles compared to TNF blockers. They highlight the benefits of IL-23 blockers, such as infrequent dosing and favorable safety profiles, especially in patients with comorbidities like inflammatory bowel disease. IL-17 blockers are praised for their rapid improvement in psoriasis symptoms, but concerns arise regarding their efficacy in psoriatic arthritis, particularly in cases of axial involvement. The discussion also touches on the importance of preventing radiographic progression in joint disease and the potential implications for treatment selection. Additionally, the dermatologists discuss the different generations of IL-17 blockers and IL-12/23 blockers, noting advancements in dosing schedules to improve treatment outcomes and patient adherence. Overall, the dermatologists emphasize the importance of considering both efficacy and safety when selecting biologic therapies for plaque psoriasis.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
